Table 1

Selection of clinical trials and approved anti-angiogenic therapies in hematological malignancies

Drug

Target

Study entities

Approved for

Receptor tyrosine kinase inhibitors

PTK787/ZK 222584 (Vatalanib^®)

VEGFR1-3, PDGFRβ, c-Kit

AML, PMF, MDS, CML, DLBCL, MM

SU5416

(Semaxinib)

VEGFR1-2, c-kit, Flt3

AML, MDS, MM, MPN

Sorafenib (Nexavar^®)

VEGFR2-3, B-Raf, Faf-1, PDGFRβ

AML, ALL, MDS, CML, CLL, NHL, MM

Advanced renal cell carcinoma, HCC

Sunitinib (Sutent^®)

VEGFR1-3, PDGFRα+β, c-kit, Flt3

AML, MDS, CLL, Myeloma, NHL

Advanced renal cell carcinoma, GIST

PKC-412 (Midostaurin)

VEGFR2, PKC, PDGFR, Flt3, c-Kit

AML

Cediranib (Recentin^®)

VEGFR1-3, PDGFRβ, c-Kit

AML, MDS, CLL

Proteasome inhibitors

Bortezomib (Velcade^®)

26S proteasome, NF-κB

AML, ALL, MDS, CML, NHL, MCL

MM, MCL

Anti-VEGF strategies

Bevacizumab (Avastin^®)

VEGF-A

AML, MDS, CLL, CML, NHL, MM

Metastatic colorectal cancer, NSCLC, breast cancer

Immunomodulatory drugs

Thalidomide

bFGF, VEGF, IL-6

AML, MDS, MPN, CLL, NHL, MM

MM

Lenalidomide (Revlimid^®)

bFGF, VEGF, IL-6

AML, MDS, CLL, NHL

MM, 5q- MDS

AML, acute myeloid leukemia; bFGF, basic fibroblast growth factor; DLBCL, diffuse large B-cell lymphoma; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; GIST, gastrointestinal stromal tumors; HCC, hepatocellular carcinoma; IL-6, Interleukin-6; NHL, non-Hodgkin lymphoma; NSCLC, non-small cell lung cancer; MCL, mantle cell lymphoma; MDS, myelodysplastic syndrome; MM, multiple myeloma; MPN, myeloproliferative neoplasm; PMF, primary myelofibrosis; VEGF, vascular endothelial growth factor.

Medinger and Mross Journal of Angiogenesis Research 2010 2:10   doi:10.1186/2040-2384-2-10